Bioethics(BOTH)
$1.250.00 (0.00%)
BOTH
Bioethics financials statements
$1.25
At close:0.00 (0.00%)
Bioethics (BOTH) Ratios
12 Followers
Bioethics Ratios
BOTH's free cash flow for Q4 2024 was $-72.24K. For the 2024 fiscal year, BOTH's free cash flow was increased by $0.00 and operating cash flow was $-72.24K. See a summary of the company’s cash flow.
| Ratios | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quick Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Solvency Ratio | -0.06 | -0.06 | -0.14 | -0.18 | -0.25 |
| Operating Cash Flow Ratio | -0.16 | -0.03 | -0.04 | -0.05 | -0.14 |
| Short-Term Operating Cash Flow Coverage | -0.26 | -0.05 | -0.06 | -0.07 | -0.19 |
| Net Current Asset Value | $ -931.22K | $ -776.26K | $ -679.12K | $ -585.91K | $ -478.96K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 39.94 | 3208.22 | 1425.71 | 538.67 | 408.86 |
| Debt-to-Equity Ratio | -0.63 | -0.57 | -0.62 | -0.67 | -0.76 |
| Debt-to-Capital Ratio | -1.70 | -1.33 | -1.63 | -2.08 | -3.21 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.02 | -0.00 | -0.00 | -0.00 | -0.00 |
| Debt Service Coverage Ratio | -0.19 | 0.00 | -0.10 | -0.13 | -0.18 |
| Interest Coverage Ratio | -2.27 | -1.08 | -1.03 | -1.24 | -1.71 |
| Debt to Market Cap | 0.34 | 0.33 | 1.42 | 0.18 | 0.28 |
| Interest Debt Per Share | 0.43 | 0.43 | 0.41 | 0.39 | 0.36 |
| Net Debt to EBITDA | -4.65 | 0.00 | -8.93 | -6.67 | -4.87 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 144.08% | 192.60% | 197.03% | 180.54% | 158.62% |
| Return on Assets (ROA) | -1206.73% | -70397.83% | -31594.24% | -14602.59% | -13347.26% |
| Return on Equity (ROE) | 19.00% | 12.51% | 13.72% | 18.29% | 24.90% |
| Return on Capital Employed (ROCE) | 13.19% | 6.50% | 6.97% | 10.13% | 15.70% |
| Return on Invested Capital (ROIC) | 35.54% | 15.12% | 18.30% | 31.16% | 66.14% |
| Return on Tangible Assets | -1206.73% | -70397.83% | -31594.24% | -14602.59% | -13347.26% |
| Earnings Yield | -10.31% | -7.13% | -31.58% | -4.97% | -9.13% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -140671.97 | -70757.67 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 140671.97 | 70757.67 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.10 | -0.02 | -0.02 | -0.02 | -0.06 |
| Free Cash Flow Per Share | -0.10 | -0.02 | -0.02 | -0.02 | -0.06 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | -9161.00 | -17173.50 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | -9161.00 | -17173.50 |
| Operating Cash Flow Coverage Ratio | -0.26 | -0.05 | -0.06 | -0.07 | -0.19 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -8.76% | -1.64% | -8.69% | -1.27% | -5.26% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.70 | -14.02 | -3.17 | -20.12 | -10.95 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -1.84 | -1.75 | -0.43 | -3.68 | -2.73 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.41 | -61.06 | -11.51 | -78.48 | -19.00 |
| Price-to-Operating Cash Flow Ratio | -11.41 | -61.06 | -11.51 | -78.48 | -19.00 |
| Price-to-Earnings Growth (PEG) Ratio | -0.24 | -3.29 | 0.24 | 3.59 | -0.99 |
| Enterprise Value Multiple | -18.63 | 0.00 | -15.20 | -43.14 | -22.31 |
| Enterprise Value | 2.29M | 1.80M | 715.44K | 2.55M | 1.67M |
| EV to EBITDA | -18.63 | 0.00 | -15.20 | -43.14 | -22.31 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -15.21 | -80.90 | -27.90 | -92.84 | -24.31 |
| EV to Operating Cash Flow | -15.21 | -80.90 | -27.90 | -92.84 | -24.31 |
| Tangible Book Value Per Share | -0.62 | -0.68 | -0.60 | -0.52 | -0.42 |
| Shareholders’ Equity Per Share | -0.62 | -0.68 | -0.60 | -0.52 | -0.42 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.12 | -0.09 | -0.08 | -0.09 | -0.10 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.44 | 1.93 | 1.97 | 1.81 | 1.59 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.85 | 0.23 | 0.28 | 0.26 | 0.58 |
Currency in USD
